MedTrace Logo

Omitting of Lymphadenectomy is Acceptable for Lung Cancer Smaller Than 6 mm in Solid Size

NCT06516796 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2713

Last updated 2024-07-24

No results posted yet for this study

Summary

Many studies suggested that selective lymph node sampling was acceptable for specific non-small cell lung cancer (NSCLC). This study aimed to evaluate the acceptability of omitting of lymphadenectomy for selected NSCLC.

Patients with small-sized (≤2 cm) NSCLC who underwent surgical resection between 2009 and 2022 were retrospectively screened.

Conditions

Interventions

OTHER

No intervention

Patients were retrospectively screened.

Sponsors & Collaborators

  • Liang Chen

    lead OTHER

Principal Investigators

  • Liang Chen, MD · The First Affiliated Hospital with Nanjing Medical University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2024-01-01
Completion
2024-02-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06516796 on ClinicalTrials.gov